News

The U.S. Food and Drug Administration (FDA) has approved Emergency Use Authorization (EUA) for investigational bamlanivimab and etesevimab as a combination therapy for the treatment of mild to

The US Food and Drug Administration (FDA) has approved Libtayo to be used for the treatment of patients having two of the most common skin cancers in the

Novartis has announced that the novel investigational treatment asciminib, specifically targeting the ABL myristoyl pocket (STAMP), has been awarded Breakthrough Therapy designation (BTD) by the US Food and

Global biopharmaceutical company Bristol Myers Squibb (BMS) has received  US Food and Drug Administration (USFDA) approval for its new CD19-directed chimeric antigen receptor (CAR) T cell therapy Breyanzi

Once the authorisation is issued, Johnson & Johnson plans to immediately supply the vaccine to the US government, with 100 million doses to be distributed in the country

The development programme commences immediately with an aim to introduce the vaccine in 2022, post regulatory approval. This vaccine will be developed with a potential for a multi-valent

With the distribution agreement, Ocugen will have the rights to the vaccine candidate in the US and will also be accountable for clinical development, regulatory approval and commercialisation

The Couvet site is a state-of-the-art manufacturing facility with commercial-scale capacity to produce capsule and tablet dosage forms. For WuXi STA, the Couvet site will be its first

The antibody therapies, which are administered via intravenous infusion, have secured Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for treating high-risk patients mild